![{[setting('site_name')]}](https://projxnews.com/uploads/setting/16983847711140531930.webp)
Cytiva has set up a 30,000 sq ft bioprocessing facility in Bengaluru to accelerate drug development for biopharmaceutical companies in India and the wider Asia-Pacific region.
The new centre is intended to help companies shorten development timelines, minimise manufacturing risks, and efficiently scale up production, in line with India’s goal of expanding its bioeconomy to $300 billion by 2030.
Featuring single-use bioreactor systems with capacities of up to 200 litres, the facility can produce toxicity batch material to support preclinical development. It is designed to provide end-to-end support for early-stage biologics development and process optimisation.
Commenting on the development, Pierre-Alain Ruffieux, Chief Operating Officer of Cytiva, said India’s scientific capabilities are integral to the global biopharma ecosystem, adding that the new facility will enable customers to move from concept to commercial impact with greater speed, reliability, and operational excellence.
News by Rahul Yelligetti.
